Article Text

Download PDFPDF
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C
  1. Alessio Aghemo1,
  2. Raffaele De Francesco2
  1. 1 Division of Gastroenterology and Hepatology, A.M. and A. Migliavacca Center for Liver Disease, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
  2. 2 Fondazione INGM, Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi”, Milan, Italy
  1. Correspondence to Dr Alessio Aghemo, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milano, Via F. Sforza 35, 20122 Milan, Italy; alessio.aghemo{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With the introduction of direct-acting antivirals (DAA), the treatment for chronic hepatitis C is evolving at an astonishingly rapid pace.1 Among DAAs, HCV NS5A inhibitors show substantial promise as anti-HCV therapeutics. NS5A inhibitors in clinical development include daclatasvir (DCV), ledipasvir, ombitasvir and MK-8742.2 With in vitro anti-HCV activities in the low picomolar range, these represent the most potent class of DAAs to target HCV. The HCV NS5A protein is known to function in multiple aspects of the HCV life cycle, including roles in viral replication and assembly, as well as complex interactions with cellular factors. Not being associated with any measurable enzymatic activity, NS5A was not considered ‘druggable’ for a very long time. In fact, the first small-molecule NS5A inhibitors were discovered by random screening using the HCV replicon system. The initial lead compounds had only moderate potency, but subsequent medicinal chemistry efforts resulted in the discovery of drugs with unparalleled antiviral activity that are characterised by highly symmetrical dimeric structure.3 The most studied of these ‘palindromic’ NS5A inhibitor class is DCV4 (formerly BMS-790052), a DAA active against a broad range of HCV genotypes for which regulatory approval both in interferon (IFN)-containing or IFN-free regimens is currently being sought. Sequencing of replicons resistant to DCV and related compounds identified NS5A as their molecular target.5 ,6 In particular, variants of NS5A M28, Q30, L31 and Y93 were found to be the most common mutations conferring broad resistance to this class of antivirals. Y93, the …

View Full Text


  • Contributors AA and RDF conceived and wrote the manuscript.

  • Competing interests AA: Advisory Board: AbbVie, Gilead Sciences. Speaker Bureau: AbbVie, Gilead Sciences, Janssen, Merck.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Hepatology
    Christophe Hézode Gideon M Hirschfield Wayne Ghesquiere William Sievert Maribel Rodriguez-Torres Stephen D Shafran Paul J Thuluvath Harvey A Tatum Imam Waked Gamal Esmat Eric J Lawitz Vinod K Rustgi Stanislas Pol Nina Weis Paul J Pockros Marc Bourlière Lawrence Serfaty John M Vierling Michael W Fried Ola Weiland Maurizia R Brunetto Gregory T Everson Stefan Zeuzem Paul Y Kwo Mark Sulkowski Norbert Bräu Dennis Hernandez Fiona McPhee Megan Wind-Rotolo Zhaohui Liu Stephanie Noviello Eric A Hughes Philip D Yin Steven Schnittman